Description

LETROZ 2.5 MG (1X5)

Indications

Letrozole, marketed under the brand name LETROZ 2.5 MG, is primarily indicated for the treatment of hormone receptor-positive breast cancer in postmenopausal women. It is particularly effective in patients with early-stage breast cancer who have undergone surgery and are receiving adjuvant therapy. Additionally, LETROZ is used in the treatment of advanced breast cancer in postmenopausal women whose disease has progressed following anti-estrogen therapy. The drug is not indicated for premenopausal women or for the treatment of hormone receptor-negative breast cancer.

Mechanism of Action

Letrozole is classified as an aromatase inhibitor. Its primary mechanism of action involves the inhibition of the aromatase enzyme, which is responsible for the conversion of androgens to estrogens in peripheral tissues. By reducing estrogen levels in the body, LETROZ effectively lowers the stimulation of estrogen-dependent tumors. This reduction in estrogen can slow down or even stop the growth of hormone-sensitive breast cancer cells, making it a crucial component in the management of certain types of breast cancer.

Pharmacological Properties

Letrozole is well-absorbed after oral administration, with peak plasma concentrations occurring approximately 1 to 2 hours post-dose. The bioavailability of LETROZ is approximately 99.9%, and it is not significantly affected by food intake. The drug is extensively metabolized in the liver, primarily via cytochrome P450 2A6 and 2C19 isoenzymes, resulting in the formation of inactive metabolites. The elimination half-life of letrozole is approximately 2 days, allowing for once-daily dosing. The drug is primarily excreted through urine, with less than 1% of the dose being eliminated unchanged.

Contraindications

LETROZ 2.5 MG is contraindicated in patients with a known hypersensitivity to letrozole or any of its excipients. It should not be administered to premenopausal women, as the drug is ineffective in this population due to the presence of ovarian estrogen production. Additionally, LETROZ should be avoided in patients with severe hepatic impairment, as the drug’s metabolism may be significantly affected, leading to increased plasma concentrations and potential toxicity.

Side Effects

The use of LETROZ 2.5 MG may be associated with several side effects. Commonly reported adverse reactions include hot flashes, joint pain, fatigue, and nausea. Other potential side effects may include headache, dizziness, and increased sweating. Serious side effects, although less common, can include bone density loss leading to osteoporosis, cardiovascular events, and liver function abnormalities. Patients should be monitored for these side effects, and any severe or persistent symptoms should be reported to a healthcare provider.

Dosage and Administration

The recommended dosage of LETROZ 2.5 MG is one tablet taken orally once daily. It can be taken with or without food, as food does not significantly affect its absorption. Treatment should continue until disease progression is observed or until the patient experiences unacceptable toxicity. In clinical practice, the duration of therapy may vary based on individual patient response and clinical judgment. Patients should be advised to adhere to the prescribed dosage and to consult their healthcare provider before making any changes to their treatment regimen.

Interactions

Letrozole may interact with other medications, which can affect its efficacy or increase the risk of adverse effects. Strong inhibitors of CYP2A6 and CYP2C19, such as certain antifungal agents and antidepressants, may increase plasma concentrations of letrozole and should be used with caution. Conversely, inducers of these enzymes may decrease the effectiveness of LETROZ. Patients should inform their healthcare provider of all medications they are currently taking, including over-the-counter drugs and supplements, to avoid potential drug interactions.

Precautions

Before initiating treatment with LETROZ 2.5 MG, healthcare providers should assess the patient’s overall health status, including any history of liver disease, osteoporosis, or cardiovascular conditions. Regular monitoring of bone mineral density is recommended, especially in patients at risk for osteoporosis. Additionally, patients should be counseled regarding the potential for side effects and the importance of reporting any unusual symptoms. Women of childbearing age should be advised to use effective contraception during treatment, as LETROZ is not indicated for use in premenopausal women, and its safety in pregnancy has not been established.

Clinical Studies

Numerous clinical studies have demonstrated the efficacy of LETROZ in the treatment of hormone receptor-positive breast cancer. One pivotal study published in the New England Journal of Medicine showed that letrozole significantly improved disease-free survival compared to tamoxifen in postmenopausal women with early-stage breast cancer. Another study indicated that letrozole was effective in prolonging progression-free survival in patients with advanced breast cancer who had previously received anti-estrogen therapy. These studies underscore the importance of letrozole as a cornerstone in the endocrine therapy of breast cancer.

Conclusion

LETROZ 2.5 MG is a vital therapeutic option for postmenopausal women diagnosed with hormone receptor-positive breast cancer. By effectively lowering estrogen levels, letrozole plays a crucial role in inhibiting the growth of estrogen-dependent tumors. While generally well-tolerated, it is essential for patients to be aware of potential side effects and drug interactions. Regular monitoring and adherence to the prescribed treatment regimen are critical for optimizing therapeutic outcomes. As with any medication, the use of LETROZ should be guided by a healthcare professional, ensuring that the benefits outweigh any potential risks.